Cargando…
Current and future options for opioid use disorder: a survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine
PURPOSE: Integrated treatment for opioid use disorder (OUD) includes opioid agonist therapy (OAT) such as methadone and buprenorphine with well-evidenced benefits. Treatment with typical existing oral medications is associated with burdens and limits to successful outcomes (frequent dosing, attendan...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188959/ https://www.ncbi.nlm.nih.gov/pubmed/30349206 http://dx.doi.org/10.2147/PPA.S180641 |
_version_ | 1783363269319196672 |
---|---|
author | Gilman, Mark Li, Li Hudson, Kerrie Lumley, Tara Myers, Georgia Corte, Camilla Littlewood, Richard |
author_facet | Gilman, Mark Li, Li Hudson, Kerrie Lumley, Tara Myers, Georgia Corte, Camilla Littlewood, Richard |
author_sort | Gilman, Mark |
collection | PubMed |
description | PURPOSE: Integrated treatment for opioid use disorder (OUD) includes opioid agonist therapy (OAT) such as methadone and buprenorphine with well-evidenced benefits. Treatment with typical existing oral medications is associated with burdens and limits to successful outcomes (frequent dosing, attendance for collection/consumption, difficulty in achieving optimal dosing, misuse, diversion, accidental exposure, and stigma from the treatment process). Novel medications include injected depot formulations with less frequent administration, providing consistent drug levels after dosing. This survey assesses the opinion of those with OUD treatment services lived experience to inform future medication choices. PATIENTS AND METHODS: A survey of people with experience of OUD pharmacotherapy – the treatment system – was completed. Participants reviewed statements describing elements of OUD care using 7-point Likert scales to indicate their level of agreement or disagreement. Data were assessed using descriptive analysis. RESULTS: In total, 35 people (16 in treatment; 19 with previous history of treatment) completed the survey. Average drug-use duration, 20 years, commonly included injected opioids. The majority agreed treatment was effective, but not tailored to their individual needs and limited normal day-to-day activities. Opinions on novel depot medications included the following: agreement on its potential to make life easier, reduce stigma, free-up time for preferred activities. Participants did not report concerns over the effectiveness and safety of depot medications, nor about reduced contact with treatment services that could be associated with less frequent dosing. CONCLUSION: This survey provides a useful initial record of the opinions of people experienced in OUD treatment services on novel depot medications, which may result in important benefits. Care providers and policy makers should continue to work with those with lived experience to understand the specific opportunity provided by such innovation. |
format | Online Article Text |
id | pubmed-6188959 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-61889592018-10-22 Current and future options for opioid use disorder: a survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine Gilman, Mark Li, Li Hudson, Kerrie Lumley, Tara Myers, Georgia Corte, Camilla Littlewood, Richard Patient Prefer Adherence Original Research PURPOSE: Integrated treatment for opioid use disorder (OUD) includes opioid agonist therapy (OAT) such as methadone and buprenorphine with well-evidenced benefits. Treatment with typical existing oral medications is associated with burdens and limits to successful outcomes (frequent dosing, attendance for collection/consumption, difficulty in achieving optimal dosing, misuse, diversion, accidental exposure, and stigma from the treatment process). Novel medications include injected depot formulations with less frequent administration, providing consistent drug levels after dosing. This survey assesses the opinion of those with OUD treatment services lived experience to inform future medication choices. PATIENTS AND METHODS: A survey of people with experience of OUD pharmacotherapy – the treatment system – was completed. Participants reviewed statements describing elements of OUD care using 7-point Likert scales to indicate their level of agreement or disagreement. Data were assessed using descriptive analysis. RESULTS: In total, 35 people (16 in treatment; 19 with previous history of treatment) completed the survey. Average drug-use duration, 20 years, commonly included injected opioids. The majority agreed treatment was effective, but not tailored to their individual needs and limited normal day-to-day activities. Opinions on novel depot medications included the following: agreement on its potential to make life easier, reduce stigma, free-up time for preferred activities. Participants did not report concerns over the effectiveness and safety of depot medications, nor about reduced contact with treatment services that could be associated with less frequent dosing. CONCLUSION: This survey provides a useful initial record of the opinions of people experienced in OUD treatment services on novel depot medications, which may result in important benefits. Care providers and policy makers should continue to work with those with lived experience to understand the specific opportunity provided by such innovation. Dove Medical Press 2018-10-11 /pmc/articles/PMC6188959/ /pubmed/30349206 http://dx.doi.org/10.2147/PPA.S180641 Text en © 2018 Gilman et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Gilman, Mark Li, Li Hudson, Kerrie Lumley, Tara Myers, Georgia Corte, Camilla Littlewood, Richard Current and future options for opioid use disorder: a survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine |
title | Current and future options for opioid use disorder: a survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine |
title_full | Current and future options for opioid use disorder: a survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine |
title_fullStr | Current and future options for opioid use disorder: a survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine |
title_full_unstemmed | Current and future options for opioid use disorder: a survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine |
title_short | Current and future options for opioid use disorder: a survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine |
title_sort | current and future options for opioid use disorder: a survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188959/ https://www.ncbi.nlm.nih.gov/pubmed/30349206 http://dx.doi.org/10.2147/PPA.S180641 |
work_keys_str_mv | AT gilmanmark currentandfutureoptionsforopioidusedisorderasurveyassessingrealworldopinionofserviceusersonnoveltherapiesincludingdepotformulationsofbuprenorphine AT lili currentandfutureoptionsforopioidusedisorderasurveyassessingrealworldopinionofserviceusersonnoveltherapiesincludingdepotformulationsofbuprenorphine AT hudsonkerrie currentandfutureoptionsforopioidusedisorderasurveyassessingrealworldopinionofserviceusersonnoveltherapiesincludingdepotformulationsofbuprenorphine AT lumleytara currentandfutureoptionsforopioidusedisorderasurveyassessingrealworldopinionofserviceusersonnoveltherapiesincludingdepotformulationsofbuprenorphine AT myersgeorgia currentandfutureoptionsforopioidusedisorderasurveyassessingrealworldopinionofserviceusersonnoveltherapiesincludingdepotformulationsofbuprenorphine AT cortecamilla currentandfutureoptionsforopioidusedisorderasurveyassessingrealworldopinionofserviceusersonnoveltherapiesincludingdepotformulationsofbuprenorphine AT littlewoodrichard currentandfutureoptionsforopioidusedisorderasurveyassessingrealworldopinionofserviceusersonnoveltherapiesincludingdepotformulationsofbuprenorphine |